News

Pregnant women made only modest dietary changes after being diagnosed with gestational diabetes, according to a study by NICHD researchers.

NICHD Director Dr. Diana Bianchi is joined by NIH Office of Research on Women’s Health Director Dr. Janine Clayton in assessing the growing maternal health crisis in the United States and describing NIH’s efforts to address it.

Trophoblasts—the outermost fetal cells of the placenta—may be able to contain SARS-CoV-2 and prevent it from spreading to the fetus even though these cells appear to be susceptible to infection by the virus, a study by NIH-funded researchers suggests. Further research into how trophoblasts might contain the virus could lead to ways to prevent COVID-19 in children and adults. The findings may also lead to insights on why fetuses are only rarely infected with SARS-CoV-2.

A team of researchers funded by the National Institutes of Health has developed a new ultrasound technique to monitor the placenta for impaired fetal blood flow early in pregnancy. The technique, which uses conventional ultrasound equipment, relies on subtle differences in the pulsation of fetal blood through the arteries at the fetal and placental ends of the umbilical cord, potentially enabling physicians to identify placental abnormalities that impair fetal blood flow and, if necessary, deliver the fetus early.

Current vaccines to prevent COVID-19 are highly effective in producing antibodies in pregnant people, resulting in more antibodies than what is generated from a natural SARS-CoV-2 virus infection, according to a study funded by the National Institutes of Health. Moreover, antibodies produced after vaccination are present in breastmilk and travel across the placenta, indicating that vaccination during pregnancy will also confer immunity to newborns.

For many COVID-19 patients, full recovery remains elusive even long after they should feel “better.” NIH recently announced research opportunities to understand COVID-19 long haulers, who have what researchers now refer to as Post-acute sequelae of SARS-CoV-2 infection (PASC). NICHD joins these opportunities while remaining focused on PASC patients within our audiences of interest—pregnant and lactating people, children, and those with disabilities.

A new study funded by the National Institutes of Health will evaluate the effects of remdesivir in pregnant women who have been prescribed the drug to treat COVID-19. The study, which will be conducted at 17 sites in the continental United States and Puerto Rico, aims to determine how pregnant women metabolize the drug and whether there are any potential side effects.

Pregnant people need to be protected through research rather than from research, the authors contend.

As the COVID-19 pandemic persists, SARS-CoV-2 vaccines offer the potential to halt the spread of the virus. Yet, we know very little about the effectiveness and safety of the vaccines during pregnancy.

NIH-funded study suggests mother-to-infant transmission appears to be rare

Increased stress may interfere with adjustment to new motherhood, mother-infant bonding

Read about NICHD’s research findings and activities from 2020.

For pregnant women with COVID-19 in the third trimester, antibodies against the SARS-CoV-2 virus appear to be transferred to the fetus at lower levels, compared to antibodies against two other respiratory diseases, suggests a study funded by the National Institutes of Health. However, one type of antibody against SARS-CoV-2 was transferred to the fetus more efficiently than the other antibodies against the virus, raising the possibility of at least some immune protection against the disease for the newborn.

Pregnant women who are infected with SARS-CoV-2, the virus that causes COVID-19, during the third trimester are unlikely to pass the infection to their newborns, suggests an NIH-funded study.

National Institutes of Health study suggests women with mood disorders, gestatational diabetes may have a higher risk.

Traces of genetic material from the placenta and other organs circulating in a pregnant woman’s blood stream could potentially be used to predict the risk for complications in later pregnancy, according to a new NICHD-supported study.

Researchers funded by the National Institutes of Health have used a rapid DNA sequencing technique to identify gene variants in roughly a third of cases of nonimmune Hydrops fetalis (NIHF), a serious condition in which a fetus develops fluid buildup inside the abdominal cavity, lungs, or other parts of the body. The findings suggest that the DNA sequencing technique, known as exome sequencing, could be used to provide information unavailable with current genetic testing methods.

The study of approximately 16,000 pregnant women will continue 12 months after childbirth and compare maternal, fetal and newborn outcomes of participants infected with the virus to those of pregnant women who have not.

New tools estimate fetal growth percentiles and velocity, and they account for racial and ethnic variations.

Researchers to evaluate medical records of 21,000 pregnant women